Zobrazeno 1 - 10
of 291
pro vyhledávání: '"S. Kochwa"'
Publikováno v:
The Mount Sinai journal of medicine, New York. 60(3)
Hypergammaglobulinemia is a consistent finding in patients within the AIDS spectrum and with hemophilia A. Serum samples from patients with these conditions were analyzed for the presence of oligoclonal banding, using a high-resolution serum protein
Autor:
M. Robert Cooper, Janet Cuttner, Thomas F. Pajak, Gibbons G. Cornwell, Sameer Rafla, O. Ross McIntyre, Robert A. Kyle, Linda P. Glowienka, Farid I. Haurani, Kurt Brunner, S. Kochwa, Richard T. Silver, Edward S. Henderson
Publikováno v:
Cancer. 50:1669-1675
A total of 361 evaluable patients with previously untreated multiple myeloma were randomized to receive oral melphalan (0.15 mg/kg/day for seven days, followed by 0.05 mg/kg/day after recovery from the nadir of the leukocytes), BCNU (150 mg/m2 intrav
Publikováno v:
Transfusion. 27:125-133
Seven serologic procedures were studied to determine their respective value in compatibility and screening tests. All seven were significantly improved by the use of 4 volumes of serum, rather than 1, with 1 volume of red cell suspension, and a low-i
Publikováno v:
Journal of Clinical Investigation. 57:194-202
The serum antitoxin response to the cytotoxin contained in preparations of Shigella dysenteriae 1 (Shiga's bacillus) exotoxin was studied in natural and experimental infections of man. Natural infection resulted in the rapid appearance of toxin-neutr
Publikováno v:
Blood. 54:13-22
Two hundred fifty-two previously untreated evaluable patients with multiple myeloma were entered into a study testing a regimen of three intravenous alkylating agents, melphalan, cyclophosphamide, and carmustine (BCNU), given in combination (BCMP) ag
Response to therapy in IgG myeloma patients excreting lambda or kappa light chains: CALGB experience
Publikováno v:
Blood. 54:23-29
Sixty-eight previously untreated patients with IgG myeloma who were entered into five protocols of Cancer and Leukemia Group B (CALGB) were studied in order to determine the possible influence of excretion of kappa versus lambda urinary light chains
Autor:
Morton Coleman, Janet Cuttner, S. Kochwa, Cooper, Thomas F. Pajak, John B. Harley, O R McIntyre
Publikováno v:
Blood. 54:13-22
Two hundred fifty-two previously untreated evaluable patients with multiple myeloma were entered into a study testing a regimen of three intravenous alkylating agents, melphalan, cyclophosphamide, and carmustine (BCNU), given in combination (BCMP) ag
Autor:
Sameer Rafla, Morton Coleman, Edward S. Henderson, Thomas F. Pajak, K Brunner, S. Kochwa, L P Glowienka, O R McIntyre, Cooper Mr, G G Cornwell rd
Publikováno v:
Journal of Clinical Oncology. 6:1481-1490
A total of 589 patients with previously untreated multiple myeloma were randomized to receive daily oral melphalan, pulse-dose intravenous (IV) melphalan, carmustine (BCNU), or lomustine (CCNU). All patients received an initial tapering course of pre
Publikováno v:
Blood. 36:137-144
The serum of a patient with chronic lymphocytic leukemia, and amyloidosis, was found to contain an unusual protein with µ chain antigenic determinants. It was devoid of light chains and was present in the form of multiple disulfide linked polymers.